BYSI
$1.07
Beyondspring
($.07)
(6.14%)
BYSI
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus:  $0.00
Revenue:  N/A
Friday
Sep 9
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when BYSI reports earnings?
Beat
Meet
Miss

Where is BYSI's stock price going from here?
Up
Flat
Down
Stock chart of BYSI
Analysts
Summary of analysts' recommendations for BYSI
Score
Grade
Pivots
Resistance
$1.26
$1.20
$1.14

$1.08

Support
$1.02
$0.96
$0.90
Tweet
Growth
Description
BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States.